{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:30Z","timestamp":1786119210828,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/iae.0b013e318154b9b9","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T18:09:06Z","timestamp":1236190146000},"page":"864-872","source":"Crossref","is-referenced-by-count":11,"title":["MULTIFOCAL ELECTRORETINOGRAPHY IN PATIENTS WITH EXUDATIVE AMD AND INTRAVITREAL TREATMENT WITH PEGAPTANIB SODIUM"],"prefix":"10.1097","volume":"27","author":[{"given":"ANDREAS","family":"LIPSKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NORBERT","family":"BORNFELD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BERNHARD","family":"JURKLIES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0039-6257(03)00030-4","article-title":"Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.","volume":"48","author":"Ambati","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"R2-10-20210130","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archopht.122.4.598","article-title":"Current concepts in the pathogenesis of age-related macular degeneration.","volume":"122","author":"Zarbin","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R3-10-20210130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease.","volume":"25","author":"Adamis","year":"2005","journal-title":"Retina"},{"key":"R4-10-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease.","volume":"22","author":"Witmer","year":"2003","journal-title":"Prog Retin Eye Res"},{"key":"R5-10-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R6-10-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R7-10-20210130","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study.","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"key":"R8-10-20210130","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration.","volume":"30","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"R9-10-20210130","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00006982-200510000-00001","article-title":"Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.","volume":"25","author":"Gonzales","year":"2005","journal-title":"Retina"},{"key":"R10-10-20210130","first-page":"1508","article-title":"2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration.","volume":"113","year":"2006","journal-title":"Ophthalmology"},{"key":"R11-10-20210130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-2005-858225","article-title":"German Ophthalmological Society; Retinological Society; Professional Association of Ophthalmologists. The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists-comments on the current therapy for neovascular AMD.","volume":"222","author":"Pauleikhoff","year":"2005","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R12-10-20210130","doi-asserted-by":"crossref","first-page":"18902","DOI":"10.1073\/pnas.0509069102","article-title":"A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.","volume":"102","author":"Lee","year":"27","journal-title":"Proc Natl Acad Sci USA 2 Dec"},{"key":"R13-10-20210130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","article-title":"Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Maturi","year":"2006","journal-title":"Retina"},{"key":"R14-10-20210130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-2005-858231","article-title":"Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA).","volume":"222","author":"Jaissle","year":"2005","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R15-10-20210130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00417-002-0439-1","article-title":"Monitoring retinal function in neovascular maculopathy using multifocal electroretinography\u2014early and long-term correlation with clinical findings.","volume":"240","author":"Jurklies","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-10-20210130","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/S0161-6420(89)32707-2","article-title":"The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study.","volume":"96","author":"Chamberlin","year":"1989","journal-title":"Ophthalmology"},{"key":"R17-10-20210130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0042-6989(92)90235-B","article-title":"The field topography of ERG components in man. 1. The photopic luminance response.","volume":"32","author":"Sutter","year":"1992","journal-title":"Vision Res"},{"key":"R18-10-20210130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archopht.122.3.325","article-title":"Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management-TAP report No. 6.","volume":"122","author":"Bressler","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R19-10-20210130","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0161-6420(02)01147-8","article-title":"Influence of photodynamic therapy in choroidal neovascularization on focal retinal function assessed with the multifocal electroretinogram and perimetry.","volume":"109","author":"Palmowski","year":"2002","journal-title":"Ophthalmology"},{"key":"R20-10-20210130","first-page":"459","article-title":"Testing central retinal function with multifocal electroretinography before and after photodynamic therapy.","volume":"100","author":"Ruether","year":"2003","journal-title":"Ophthalmologe"},{"key":"R21-10-20210130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.eye.6701777","article-title":"Aging and mfERG topography.","volume":"20","author":"Tam","year":"2006","journal-title":"Eye"},{"key":"R22-10-20210130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1364\/JOSAA.19.000173","article-title":"Decline of photopic multifocal electroretinogram responses with age is due primarily to preretinal optical factors.","volume":"19","author":"Fortune","year":"2002","journal-title":"J Opt Soc Am A Opt Image Sci Vis"},{"key":"R23-10-20210130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2003.04.011","article-title":"Voluntary suppression of the multifocal electroretinogram.","volume":"111","author":"Vrabec","year":"2004","journal-title":"Ophthalmology"},{"key":"R24-10-20210130","first-page":"2844","article-title":"Multifocal electroretinogram in myopia.","volume":"38","author":"Kawabata","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-10-20210130","first-page":"41","article-title":"Effects on refractive blur on the multifocal electroretinogram.","volume":"98","author":"Palmowski","year":"2000","journal-title":"Doc Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200709000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:40:55Z","timestamp":1786038055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200709000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318154b9b9","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}